



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)



<sup>a</sup>:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.

Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.

Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.


Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure  
15.4.2.9.sas

Merck Serono  
EMR 200125-001  
Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/Figures/Figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: \_\_\_\_\_



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas

Merck Serono  
EMR 200125-001

Page 6 of 216  
Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 1059




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




⊖: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 15.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number: 1




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Merck Serono  
EMR 200125-001

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: :




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




⊖: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 15.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TPL programs/figures/figure  
15.4.2.9.sas




Merck Serono  
EMR 200125-001

Confidential

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: .




0: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/Figure 15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
 Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
 Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
 Source: Listing 16.2.5.2


/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TEL programs/figures/Figure 15.4.2.9.sas





Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number: 110719




⊘: Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas

Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values) (Safety Population)

Subject ID/Random Number:




@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas



Figure 15.4.2.9 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T4 Values)  
(Safety Population)

Subject ID/Random Number:



@:Subjects excluded from PK Population; Horizontal lines represent the Baseline of the respective treatments.  
Test: 600 µg (3\*200 µg tablets) levothyroxine new formulation.  
Reference: 600 µg (3\*200 µg tablets) levothyroxine old formulation.  
Source: Listing 16.2.5.2

/project24/ep/blinded/e210899\_merc/stats/versioncontrol/primary/scripts/program/main/TFL programs/figures/figure  
15.4.2.9.sas